RAC1 and ovarian carcinoma: Our results are similar to the previous research that EGFR is reported to overexpressed in most ovarian cancer [36], and the activation of the EGFR pathway has impact on invasion and metastasis as well as cell survival through the MAPK/ERK, PI3K/AKT and Rac1 pathways [37–41].